European Commission Grants Five-Year License Renewal for Glyphosate

The approval of the Roundup ingredient follows an extensive debate amidst conflicting evidence over the health effects of the world’s most popular weed killer.

Written byKatarina Zimmer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ISTOCK, STANDRETThe European Commission voted yesterday (November 27) to approve a license renewal for glyphosate, the active ingredient in Monsanto’s popular herbicide Roundup. European farmers will be able to use glyphosate for another five years.

The decision follows months of indecision among members of the Commission’s Committee on Plants, Animals, Food and Feed about the extension, fueled by conflicting evidence over its potential effects on human and environmental health. The Commission had initially proposed a 10-year extension on glyphosate use, which was rejected by the majority of countries who voted. Eighteen countries voted in favor of a five-year renewal, overriding countries including France, Italy, and Austria, which opposed the decision over health concerns, according to Science.

Germany was among the countries that had voted in favor of the renewal, yet German Chancellor Angela Merkel evidently regretted the decision, according to Reuters. “This did not comply with the instructions worked out by the federal government,” Merkel said in a news conference ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies